Array
(
[0] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1728374011:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 11
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 10MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 1
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4665
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => Rupataget tablet is indicated for symptomatic treatment of allergic rhinitis and urticaria.
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Rupatadine
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Antihistaminic/Antiallergic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 455
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4668
[ID] => 4668
[post_author] => 1
[post_content] => Rupataget tablet is indicated for symptomatic treatment of allergic rhinitis and urticaria.
[post_date] => 2024-10-08 07:48:58
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Rupataget™
[post_type] => product
[slug] => rupataget
[__type:protected] =>
[_edit_lock] => 1728374011:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 11
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 10MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 1
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4665
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => Rupataget tablet is indicated for symptomatic treatment of allergic rhinitis and urticaria.
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Rupatadine
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Antihistaminic/Antiallergic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 455
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[post_date_gmt] => 2024-10-08 07:48:58
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => rupataget
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-08 07:48:58
[post_modified_gmt] => 2024-10-08 07:48:58
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4668
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[1] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1728374161:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 7
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4664
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => Finone (Finerenone) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Finerenone
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Diuretics
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 724
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[_wp_old_date] => 2024-09-18
[getz_products_attributes_0_product_availability_0_products_strengths] => 10MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 20MG
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4656
[ID] => 4656
[post_author] => 1
[post_content] => Finone (Finerenone) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
[post_date] => 2024-10-08 07:44:26
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Finone™
[post_type] => product
[slug] => finone
[__type:protected] =>
[_edit_lock] => 1728374161:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 7
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4664
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => Finone (Finerenone) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Finerenone
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Diuretics
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 724
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[_wp_old_date] => 2024-09-18
[getz_products_attributes_0_product_availability_0_products_strengths] => 10MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 20MG
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[post_date_gmt] => 2024-10-08 07:44:26
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => finone
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-08 07:44:50
[post_modified_gmt] => 2024-10-08 07:44:50
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4656
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[2] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1725626517:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 4
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 15MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 1
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4642
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => - Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
-Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
- Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
- Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Adults with active non-radiographic axial spondyloarthritis having objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal Anti-inflammatory drugs (NSAIDs)
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Upadacitinib
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => JAK inhibitors
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 450
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4637
[ID] => 4637
[post_author] => 1
[post_content] => - Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers
- Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
- Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable
- Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers
- Adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent
- Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers
- Adults with active non-radiographic axial spondyloarthritis having objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal Anti-inflammatory drugs (NSAIDs)
[post_date] => 2024-09-06 11:17:04
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Upaget™
[post_type] => product
[slug] => upaget
[__type:protected] =>
[_edit_lock] => 1725626517:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 4
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 15MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 1
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4642
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => - Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
-Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
- Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
- Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Adults with active non-radiographic axial spondyloarthritis having objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal Anti-inflammatory drugs (NSAIDs)
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Upadacitinib
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => JAK inhibitors
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 450
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[post_date_gmt] => 2024-09-06 11:17:04
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => upaget
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-06 12:33:35
[post_modified_gmt] => 2024-09-06 12:33:35
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4637
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[3] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1724415366:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 11
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablets
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 4
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4634
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Empagliflozin + Linagliptin + Metformin HCl
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Diabetic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 35
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[getz_products_attributes_0_product_availability_0_products_strengths] => 5mg+2.5mg+1000mg
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 10mg+5mg+1000mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_2_products_strengths] => 12.5mg+2.5mg+1000mg
[_getz_products_attributes_0_product_availability_2_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_2_product_link] =>
[_getz_products_attributes_0_product_availability_2_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_3_products_strengths] => 25mg+5mg+1000mg
[_getz_products_attributes_0_product_availability_3_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_3_product_link] =>
[_getz_products_attributes_0_product_availability_3_product_link] => field_5c0657259e1a3
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4632
[ID] => 4632
[post_author] => 1
[post_content] => Diampa LXR is a combination of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
[post_date] => 2024-08-23 11:10:55
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Diampa™ LXR
[post_type] => product
[slug] => diampa-lxr
[__type:protected] =>
[_edit_lock] => 1724415366:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 11
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablets
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 4
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4634
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Empagliflozin + Linagliptin + Metformin HCl
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Diabetic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 35
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[getz_products_attributes_0_product_availability_0_products_strengths] => 5mg+2.5mg+1000mg
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 10mg+5mg+1000mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_2_products_strengths] => 12.5mg+2.5mg+1000mg
[_getz_products_attributes_0_product_availability_2_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_2_product_link] =>
[_getz_products_attributes_0_product_availability_2_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_3_products_strengths] => 25mg+5mg+1000mg
[_getz_products_attributes_0_product_availability_3_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_3_product_link] =>
[_getz_products_attributes_0_product_availability_3_product_link] => field_5c0657259e1a3
[post_date_gmt] => 2024-08-23 11:10:55
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => diampa-lxr
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-23 12:01:01
[post_modified_gmt] => 2024-08-23 12:01:01
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4632
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[4] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1716207925:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 7
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] =>
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 50MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 100MG
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4556
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Trelagliptin
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Diabetic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 143
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4553
[ID] => 4553
[post_author] => 1
[post_content] => Long acting DPP-IV inhibitor indicated for the treatment of Type II diabetes mellitus. It is given as once weekly dose.
[post_date] => 2024-05-20 11:37:35
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Trelaget™
[post_type] => product
[slug] => trelaget
[__type:protected] =>
[_edit_lock] => 1716207925:1
[_edit_last] => 1
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 7
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] =>
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 50MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 100MG
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4556
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Trelagliptin
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Diabetic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_primary_category] => 143
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[post_date_gmt] => 2024-05-20 11:37:35
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => trelaget
[to_ping] =>
[pinged] =>
[post_modified] => 2024-05-20 11:53:40
[post_modified_gmt] => 2024-05-20 11:53:40
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4553
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[5] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1691412518:22
[rank_math_seo_score] => 7
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[_edit_last] => 1
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 1
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 2
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] =>
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] => 2
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => Onseget (Ondansetron) is indicated for the treatment of:
Adults
Prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting
Pediatric Population
Management of chemotherapy-induced nausea and vomiting in children aged ≥ 6 months, and for the prevention and treatment of post-operative nausea and vomiting in Children aged ≥1 month.
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Ondansetron
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Emetic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_internal_links_processed] => 1
[rank_math_primary_category] => 450
[rank_math_primary_filters] => 17
[rank_math_primary_countries] => 40
[getz_products_attributes_0_product_availability_0_products_strengths] => 8MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_1_product_type] => Injection
[_getz_products_attributes_1_product_type] => field_57aacd67c871f
[getz_products_attributes_1_product_availability_0_products_strengths] => 4mg/2ml
[_getz_products_attributes_1_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_1_product_availability_0_product_link] =>
[_getz_products_attributes_1_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_1_product_availability] => 2
[_getz_products_attributes_1_product_availability] => field_57aacbc108025
[getz_products_attributes_1_product_availability_1_products_strengths] => 8mg/4ml
[_getz_products_attributes_1_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_1_product_availability_1_product_link] =>
[_getz_products_attributes_1_product_availability_1_product_link] => field_5c0657259e1a3
[multiple_leaflets_0_leaflet_title] => Onseget (Injection)
[_multiple_leaflets_0_leaflet_title] => field_5858c432751a4
[multiple_leaflets_0_leaflet_file] => 4393
[_multiple_leaflets_0_leaflet_file] => field_5858c43e751a5
[multiple_leaflets_1_leaflet_title] => Onseget (Tablet)
[_multiple_leaflets_1_leaflet_title] => field_5858c432751a4
[multiple_leaflets_1_leaflet_file] => 4394
[_multiple_leaflets_1_leaflet_file] => field_5858c43e751a5
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4392
[ID] => 4392
[post_author] => 1
[post_content] => Onseget™ (Ondansetron) is indicated for the treatment of:
Adults
Prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting.
Pediatric Population
Management of chemotherapy-induced nausea and vomiting in children aged ≥ 6 months, and for the prevention and treatment of post-operative nausea and vomiting in Children aged ≥1 month.
[post_date] => 2023-02-24 05:09:24
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Onseget™
[post_type] => product
[slug] => onseget
[__type:protected] =>
[_edit_lock] => 1691412518:22
[rank_math_seo_score] => 7
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[_edit_last] => 1
[attributes] =>
[_attributes] => field_57879498f70b4
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 1
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 2
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] =>
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] => 2
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] => Onseget (Ondansetron) is indicated for the treatment of:
Adults
Prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, and for the prevention and treatment of post-operative nausea and vomiting
Pediatric Population
Management of chemotherapy-induced nausea and vomiting in children aged ≥ 6 months, and for the prevention and treatment of post-operative nausea and vomiting in Children aged ≥1 month.
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[generic_name] => Ondansetron
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Emetic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[rank_math_internal_links_processed] => 1
[rank_math_primary_category] => 450
[rank_math_primary_filters] => 17
[rank_math_primary_countries] => 40
[getz_products_attributes_0_product_availability_0_products_strengths] => 8MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_1_product_type] => Injection
[_getz_products_attributes_1_product_type] => field_57aacd67c871f
[getz_products_attributes_1_product_availability_0_products_strengths] => 4mg/2ml
[_getz_products_attributes_1_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_1_product_availability_0_product_link] =>
[_getz_products_attributes_1_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_1_product_availability] => 2
[_getz_products_attributes_1_product_availability] => field_57aacbc108025
[getz_products_attributes_1_product_availability_1_products_strengths] => 8mg/4ml
[_getz_products_attributes_1_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_1_product_availability_1_product_link] =>
[_getz_products_attributes_1_product_availability_1_product_link] => field_5c0657259e1a3
[multiple_leaflets_0_leaflet_title] => Onseget (Injection)
[_multiple_leaflets_0_leaflet_title] => field_5858c432751a4
[multiple_leaflets_0_leaflet_file] => 4393
[_multiple_leaflets_0_leaflet_file] => field_5858c43e751a5
[multiple_leaflets_1_leaflet_title] => Onseget (Tablet)
[_multiple_leaflets_1_leaflet_title] => field_5858c432751a4
[multiple_leaflets_1_leaflet_file] => 4394
[_multiple_leaflets_1_leaflet_file] => field_5858c43e751a5
[post_date_gmt] => 2023-02-24 05:09:24
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => onseget
[to_ping] =>
[pinged] =>
[post_modified] => 2023-02-24 05:14:31
[post_modified_gmt] => 2023-02-24 05:14:31
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4392
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[6] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1645591099:2
[_edit_last] => 1
[attributes] =>
[_attributes] => field_57879498f70b4
[item_content] => Rovista®EZ is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated:
- as an adjunct to diet in patients with primary (heterozygous familial and non-familial) hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C)
- alone or as an adjuct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4305
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[generic_name] => Rosuvastatin + Ezetimibe
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Lipidemic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_estimated-reading-time-minutes] =>
[_yoast_wpseo_content_score] => 90
[getz_products_attributes_0_product_type] => Film-Coated Tablets
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 5mg + 10mg
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 3
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes_0_product_availability_1_products_strengths] => 10mg + 10mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_2_products_strengths] => 20mg + 10mg
[_getz_products_attributes_0_product_availability_2_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_2_product_link] =>
[_getz_products_attributes_0_product_availability_2_product_link] => field_5c0657259e1a3
[_yoast_wpseo_primary_category] => 147
[_yoast_wpseo_primary_filters] => 66
[_yoast_wpseo_primary_countries] => 40
[_yoast_wpseo_metadesc] => Rovista®EZ is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated: as an adjunct to diet in patients with primary (heterozygous familial and non-familial) hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); alone or as an adjuct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C
[rank_math_primary_category] => 147
[rank_math_primary_filters] => 66
[rank_math_primary_countries] => 40
[rank_math_description] => Rovista®EZ is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated: as an adjunct to diet in patients with primary (heterozygous familial and non-familial) hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); alone or as an adjuct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 4
[rank_math_internal_links_processed] => 1
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4303
[ID] => 4303
[post_author] => 1
[post_content] => Rovista®EZ is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated:
- as an adjunct to diet in patients with primary (heterozygous familial and non-familial) hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C)
- alone or as an adjuct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C
[post_date] => 2022-02-21 05:48:33
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Rovista®EZ
[post_type] => product
[slug] => rovistaez
[__type:protected] =>
[_edit_lock] => 1645591099:2
[_edit_last] => 1
[attributes] =>
[_attributes] => field_57879498f70b4
[item_content] => Rovista®EZ is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated:
- as an adjunct to diet in patients with primary (heterozygous familial and non-familial) hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C)
- alone or as an adjuct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4305
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[generic_name] => Rosuvastatin + Ezetimibe
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Lipidemic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_estimated-reading-time-minutes] =>
[_yoast_wpseo_content_score] => 90
[getz_products_attributes_0_product_type] => Film-Coated Tablets
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 5mg + 10mg
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 3
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes_0_product_availability_1_products_strengths] => 10mg + 10mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_2_products_strengths] => 20mg + 10mg
[_getz_products_attributes_0_product_availability_2_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_2_product_link] =>
[_getz_products_attributes_0_product_availability_2_product_link] => field_5c0657259e1a3
[_yoast_wpseo_primary_category] => 147
[_yoast_wpseo_primary_filters] => 66
[_yoast_wpseo_primary_countries] => 40
[_yoast_wpseo_metadesc] => Rovista®EZ is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated: as an adjunct to diet in patients with primary (heterozygous familial and non-familial) hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); alone or as an adjuct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C
[rank_math_primary_category] => 147
[rank_math_primary_filters] => 66
[rank_math_primary_countries] => 40
[rank_math_description] => Rovista®EZ is a combination of rosuvastatin, an HMG CoA-reductase inhibitor (statin), and ezetimibe, a dietary cholesterol absorption inhibitor, indicated: as an adjunct to diet in patients with primary (heterozygous familial and non-familial) hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C); alone or as an adjuct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 4
[rank_math_internal_links_processed] => 1
[post_date_gmt] => 2022-02-21 05:48:33
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => rovistaez
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-21 08:11:45
[post_modified_gmt] => 2022-02-21 08:11:45
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4303
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[7] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1642412048:1
[_edit_last] => 1
[attributes] =>
[_attributes] => field_57879498f70b4
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4286
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[generic_name] => Amlodipine + Telmisartan
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Hypertensive
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_content_score] => 60
[_yoast_wpseo_estimated-reading-time-minutes] =>
[_yoast_wpseo_primary_category] => 672
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 4
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[_yoast_wpseo_primary_filters] => 21
[_yoast_wpseo_primary_countries] => 40
[getz_products_attributes_0_product_availability_0_products_strengths] => 5mg + 40mg
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 5mg + 80mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_2_products_strengths] => 10mg + 40mg
[_getz_products_attributes_0_product_availability_2_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_2_product_link] =>
[_getz_products_attributes_0_product_availability_2_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_3_products_strengths] => 10MG + 80MG
[_getz_products_attributes_0_product_availability_3_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_3_product_link] =>
[_getz_products_attributes_0_product_availability_3_product_link] => field_5c0657259e1a3
[rank_math_primary_category] => 672
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 8
[rank_math_internal_links_processed] => 1
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4289
[ID] => 4289
[post_author] => 1
[post_content] => Tasmi®-AM (Amlodipine + Telmisartan) is indicated for:
- the treatment of hypertension alone or with other antihypertensive agents.
- the initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
[post_date] => 2022-01-17 09:35:03
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Tasmi®-AM
[post_type] => product
[slug] => tasmi-am
[__type:protected] =>
[_edit_lock] => 1642412048:1
[_edit_last] => 1
[attributes] =>
[_attributes] => field_57879498f70b4
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4286
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[generic_name] => Amlodipine + Telmisartan
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Hypertensive
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_content_score] => 60
[_yoast_wpseo_estimated-reading-time-minutes] =>
[_yoast_wpseo_primary_category] => 672
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability] => 4
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[_yoast_wpseo_primary_filters] => 21
[_yoast_wpseo_primary_countries] => 40
[getz_products_attributes_0_product_availability_0_products_strengths] => 5mg + 40mg
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_1_products_strengths] => 5mg + 80mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_2_products_strengths] => 10mg + 40mg
[_getz_products_attributes_0_product_availability_2_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_2_product_link] =>
[_getz_products_attributes_0_product_availability_2_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability_3_products_strengths] => 10MG + 80MG
[_getz_products_attributes_0_product_availability_3_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_3_product_link] =>
[_getz_products_attributes_0_product_availability_3_product_link] => field_5c0657259e1a3
[rank_math_primary_category] => 672
[rank_math_primary_filters] => 21
[rank_math_primary_countries] => 40
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 8
[rank_math_internal_links_processed] => 1
[post_date_gmt] => 2022-01-17 09:35:03
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => tasmi-am
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-17 09:35:45
[post_modified_gmt] => 2022-01-17 09:35:45
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4289
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[8] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1708404359:1
[_edit_last] => 1
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 10MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4152
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[attributes] =>
[_attributes] => field_57879498f70b4
[generic_name] => Rosuvastatin
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Lipidemic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_primary_countries] => 448
[_yoast_wpseo_content_score] => 30
[_yoast_wpseo_estimated-reading-time-minutes] => 2
[_yoast_wpseo_primary_category] => 450
[_yoast_wpseo_primary_filters] => 21
[rank_math_primary_countries] => 448
[rank_math_primary_category] => 450
[rank_math_primary_filters] => 21
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 23
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 9
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[getz_products_attributes_0_product_availability_1_products_strengths] => 20MG
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4114
[ID] => 4114
[post_author] => 2
[post_content] => For the treatment of:
• Hyperlipidemia and mixed dyslipidemia as adjunctive therapy to diet to reduce elevated Total-C, LDL-C,
ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
• Pediatric patients 10 to 17 years of age with heterozygous familal hypercholesterolemia (HeFH) as adjunct to diet to reduce Total-C, LDL-C and ApoB levels in adolescent boys and girls, who are at least one year postmenarche, 10-17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C greater than 190 mg/dL or greater than 160 mg/dL and there is a positive family his tory of premature cardiovascular disease (CVD) or two or more other CVD risk factors.
• Hypertriglyceridemia as adjunctive therapy to diet for the treatment of adult patients with
hypertriglyceridemia.
• Primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia) as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia).
• Homozygous familal hypercholesterolemia as adjunctive therapy to other lipid lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia.
• Slowing of the progression of atherosclerosis as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.
• Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.
[post_date] => 2021-08-20 08:01:38
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Rovista™
[post_type] => product
[slug] => rovista-10
[__type:protected] =>
[_edit_lock] => 1708404359:1
[_edit_last] => 1
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 10MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4152
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[attributes] =>
[_attributes] => field_57879498f70b4
[generic_name] => Rosuvastatin
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Lipidemic
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_primary_countries] => 448
[_yoast_wpseo_content_score] => 30
[_yoast_wpseo_estimated-reading-time-minutes] => 2
[_yoast_wpseo_primary_category] => 450
[_yoast_wpseo_primary_filters] => 21
[rank_math_primary_countries] => 448
[rank_math_primary_category] => 450
[rank_math_primary_filters] => 21
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 23
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 9
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[getz_products_attributes_0_product_availability_1_products_strengths] => 20MG
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[post_date_gmt] => 2021-08-20 08:01:38
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => rovista-10
[to_ping] =>
[pinged] =>
[post_modified] => 2024-02-19 10:29:40
[post_modified_gmt] => 2024-02-19 10:29:40
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4114
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
[9] => Timber\Post Object
(
[ImageClass] => Timber\Image
[PostClass] => Timber\Post
[TermClass] => Timber\Term
[object_type] => post
[custom] => Array
(
[_edit_lock] => 1708338369:1
[_edit_last] => 1
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 5MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4118
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[attributes] =>
[_attributes] => field_57879498f70b4
[generic_name] => Ivabradine
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Anginal
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_primary_countries] => 448
[_yoast_wpseo_content_score] => 30
[_yoast_wpseo_estimated-reading-time-minutes] => 1
[_yoast_wpseo_primary_category] => 355
[_yoast_wpseo_primary_filters] => 21
[rank_math_primary_countries] => 448
[rank_math_primary_category] => 355
[rank_math_primary_filters] => 21
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 27
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 11
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[getz_products_attributes_0_product_availability_1_products_strengths] => 7.5mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
)
[___content:protected] =>
[_permalink:protected] =>
[_next:protected] => Array
(
)
[_prev:protected] => Array
(
)
[_css_class:protected] =>
[id] => 4117
[ID] => 4117
[post_author] => 2
[post_content] => Coronory Artery Disease (CAD)
• Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm:
• Who are unable to tolerate or have a contraindication to beta blockers, or
• In combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm.
Chronic Heart Failure (CHF)
• Symptomatic treatment of chronic heart failure of NYHA Classes II or III and with documented left ventricular ejection fraction (LVEF) ≤ 35% in adult patients in sinus rhythm and with heart rate at or above 77 bpm, in combination with optimal standard chronic heart failure treatment.
[post_date] => 2021-08-17 12:59:33
[post_excerpt] =>
[post_parent] => 0
[post_status] => publish
[post_title] => Sivab™
[post_type] => product
[slug] => sivab-2
[__type:protected] =>
[_edit_lock] => 1708338369:1
[_edit_last] => 1
[getz_products_attributes_0_product_type] => Tablet
[_getz_products_attributes_0_product_type] => field_57aacd67c871f
[getz_products_attributes_0_product_availability_0_products_strengths] => 5MG
[_getz_products_attributes_0_product_availability_0_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_0_product_link] =>
[_getz_products_attributes_0_product_availability_0_product_link] => field_5c0657259e1a3
[getz_products_attributes_0_product_availability] => 2
[_getz_products_attributes_0_product_availability] => field_57aacbc108025
[getz_products_attributes] => 1
[_getz_products_attributes] => field_57aacb9008024
[product_leaflet_text] => Prescribing Information
[_product_leaflet_text] => field_5858c3e8751a2
[product_leaflet] => 4118
[_product_leaflet] => field_58256525c3163
[multiple_leaflets] =>
[_multiple_leaflets] => field_5858c3fb751a3
[_] => field_5c41afb5d5896
[item_content] =>
[_item_content] => field_5770d187c6470
[item_image] =>
[_item_image] => field_5770d19cc6471
[attributes] =>
[_attributes] => field_57879498f70b4
[generic_name] => Ivabradine
[_generic_name] => field_576e8d032aabe
[therapeutic_segment] => Anti-Anginal
[_therapeutic_segment] => field_577145185eefa
[redirector_active] => 0
[_redirector_active] => field_576392a2c282d
[recommended_articles] =>
[_recommended_articles] => field_5788f2cab8fde
[_yoast_wpseo_primary_countries] => 448
[_yoast_wpseo_content_score] => 30
[_yoast_wpseo_estimated-reading-time-minutes] => 1
[_yoast_wpseo_primary_category] => 355
[_yoast_wpseo_primary_filters] => 21
[rank_math_primary_countries] => 448
[rank_math_primary_category] => 355
[rank_math_primary_filters] => 21
[rank_math_news_sitemap_robots] => index
[rank_math_robots] => Array
(
[0] => index
)
[rank_math_analytic_object_id] => 27
[rank_math_internal_links_processed] => 1
[rank_math_seo_score] => 11
[rank_math_contentai_score] => Array
(
[wordCount] => 100
[linkCount] => 0
[headingCount] => 100
[mediaCount] => 62.22
)
[getz_products_attributes_0_product_availability_1_products_strengths] => 7.5mg
[_getz_products_attributes_0_product_availability_1_products_strengths] => field_57aaccbd3b9c5
[getz_products_attributes_0_product_availability_1_product_link] =>
[_getz_products_attributes_0_product_availability_1_product_link] => field_5c0657259e1a3
[post_date_gmt] => 2021-08-17 12:59:33
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sivab-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-02-19 10:27:30
[post_modified_gmt] => 2024-02-19 10:27:30
[post_content_filtered] =>
[guid] => https://getzpharma.com/?post_type=product&p=4117
[menu_order] => 0
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
[status] => publish
)
)